Concepedia

Kirsten B. Goldberg

KB

Statistics

Publications

60

Citations

6.6K

H-Index

45

Active since

2017

Affiliations

United States Food and Drug Administration(Current)

Center for Drug Evaluation and Research

Center for Devices and Radiological Health

Kirsten B. Goldberg is an author at United States Food and Drug Administration specializing in medicine, oncology, and pharmacology.

ORCID

Publications per year

2017–2025

60

Publications

60

Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody

V. Ellen Maher, Laura L. Fernandes, Chana Weinstock et al. · Journal of Clinical Oncology · 2019 · 346 citations

, , +17

FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia

Aviva C. Krauss, Xin Gao, Liang Li et al. · Clinical Cancer Research · 2018 · 327 citations · Full text

, , +17

CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis

Jennifer Gao, Joyce Cheng, Erik Bloomquist et al. · The Lancet Oncology · 2019 · 297 citations

, , +17

FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond

Lee H. Pai-Scherf, Gideon M. Blumenthal, Hongshan Li et al. · The Oncologist · 2017 · 292 citations · Full text

, , +16

FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1

Lola A. Fashoyin‐Aje, Martha Donoghue, Huanyu Chen et al. · The Oncologist · 2018 · 227 citations · Full text

, , +17

1–5 of 60